Investor News

INVESTOR NEWS

2018

3. December 2018 - 2018 Developing

MPH Health Care AG: Investments developing positive

  •  CR Capital Real Estate raises sales and profit forecast
  • Haemato increases earnings by approx. 50% in the first 9 months
  • M1 Kliniken opens further locations

Berlin, 03 December 2018: The affiliated companies of MPH Health Care AG (ISIN: DE000A0L1H32) have confirmed their growth course with positive news.

CR Capital Real Estate AG has significantly increased its sales and profit forecast for the current year 2018. The real estate company focuses on the creation of affordable living space in the metropolises of Berlin and Leipzig and their environs. Group sales in 2018 are expected to increase from EUR 10.4 million in the previous year to over EUR 20 million. The annual surplus is to rise from 5.8 million euros to over 7 million euros. The project in Schkeuditz with 96 terraced houses is decisive for the positive development. In addition, plots close to Berlin were acquired. Here, too, semi-detached and terraced houses are expected to be built.

HAEMATO AG reported on the development in the first nine months of 2018. The provider of special pharmaceuticals increased its profit by 50.5 percent from EUR 3.9 million to EUR 5.87 million compared to the same period of the previous year. Sales increased slightly from EUR 211.3 million to EUR 212.8 million. HAEMATO specializes in drugs for the treatment of chronic diseases and sees further growth potential. In addition, the operating margin is to be increased sustainably. Therefor, the Executive Board is working on optimizing business processes through digitization.

M1 Kliniken AG, the number 1 in the field of beauty medicine in Germany, continues its expansion course in 2018. 4 new specialist centres have been opened so far this year. Two more are to follow by the end of the year. The M1 Group will thus operate a total of 24 specialist centres for aesthetic treatments by the end of 2018. The increase of more than 30% compared to the previous year is in line with corporate planning. M1 Kliniken AG is thus creating an important condition for a further significant increase in sales in the coming year.

read more

30. October 2018 - Q3 Results 2018

Investment company MPH Health Care AG increases net asset value by 27.6 % to EUR 6.56 per share as of 30.09.2018

  • Net income for the period of 48.90 million euros
  • Equity ratio increases to 94.2 %

Berlin, 30. Oktober 2018: MPH Health Care AG (ISIN: DE000A0L1H32) continued to benefit from the successful development of its portfolio companies in the first nine months of 2018. The net asset value (NAV) per share rose year-on-year by 27.6 % from EUR 5.14 to EUR 6.56 as of September 30, 2018. This means that the NAV is still well above the current share price (Xetra closing price on October 29, 2018: EUR 4.17).

In the first nine months of 2018, MPH generated a preliminary IFRS period surplus of EUR 48.90 million (previous year: EUR 11.22 million). This pleasing result was achieved through a corresponding increase in the value of financial investments. Compared with the end of 2017, equity rose from EUR 240.67 million to EUR 281.00 million.

“The health care and construction industries in Germany have been growing faster than the economy as a whole for years, and with our investments we benefit systematically, e.g. through the growth of HAEMATO AG with pharmaceuticals in the insurance-financed market, M1 Kliniken AG in the private payer market and CR Capital Real Estate AG in the affordable new residential constructions for owner-occupiers. We are therefore confident that this positive development will continue,” says Patrick Brenske, CEO of MPH.

read more

31. August 2018 - Interim Report 2018

Investment company MPH Health Care AG with successful first half-year of 2018: Net asset value rises by 43 % to EUR 6.93 per share

  • Net earnings EUR 55.9 million (previous year: EUR -2.2 million)
  • Investments: HAEMATO has more than doubled its EBIT; M1 Kliniken grows by 30 %; CR Capital benefits from great interest in the “Halle Gardens” construction project in Schkeuditz/Leipzig
  • Dividend payment of 20 cents per share (previous year: 12 cents) made in July

Berlin, 31 August 2018: MPH Health Care AG (ISIN: DE000A0L1H32) benefited from the successful development of its portfolio companies in the first half-year of 2018. The net asset value (NAV) per share rose year-on-year by 43.4 % from EUR 4.83 to EUR 6.93. With this, the NAV continues to exceed the current share price considerably (Xetra closing on August 30: EUR 4.54).

IFRS equity capital amounted to EUR 296.6 million at the reporting date of 30 June 2018 (H1 2017: EUR 206.6 million). MPH increased its net earnings (IFRS) in the first half-year of 2018 to EUR 55.9 million (H1 2017: EUR -2.2 million).

“Our listed investments in HAEMATO, M1 Kliniken and CR Capital Real Estate have continued their successful development in the first half-year of 2018,” says Patrick Brenske, CEO of MPH. “With our focus on growth companies of the German health care market, we systematically benefit from the industry’s above-average development compared to the overall economy. We were therefore able to pay a significantly higher dividend of 20 cents per share in July 2018.”

The three major portfolio companies of MPH Health Care AG recorded a positive development in the first half-year of 2018.

HAEMATO AG, a pharmaceutical company focusing on the growth markets of high-priced specialty pharmaceuticals, more than doubled its earnings before interest and taxes (EBIT) – with slightly increasing sales – to EUR 6.5 million compared to the previous year in the first half-year of 2018.

M1 Kliniken AG, a leading private provider of health services in the field of aesthetic medicine in Germany, continued its profitable growth course and increased Group sales by 30% to EUR 28.9 million. For the second half-year of 2018, not only additional M1 Med Beauty locations, but also further specialist centres for aesthetic dental treatments under the new brand “M1 Dental” are planned. In addition, M1 is targeting its internationalisation. The first international location is to be opened in Vienna in the second half of 2018.

CR Capital Real Estate AG, which focuses on project developments in the residential and health care real estate sectors, has successfully continued its current construction project “Halle Gardens” in Schkeuditz/Leipzig. The first residential units were handed over to the new owners in April. The complete handover of the first construction phase with 96 residential units is to take place until autumn 2018. Due to the high demand, CR has already acquired further adjacent areas and is planning further new buildings there. In addition, CR has secured plots in the Berlin surroundings, in attractive quality locations with good infrastructure.

 The Half Year Report 2018 of MPH Health Care will be available for download from www.mph-ag.de/investor-relations later today.

 

read more

13. July 2018 - hv_2018

Significant dividend increase from 0.12 EUR to 0.20 EUR per share approved

  • Dividend yield at 4 %
  • Annual general meeting approves all agenda items

Berlin, May 11, 2018: MPH Health Care AG (ISIN: DE000A0L1H32) will continue to benefit from the successful development of its associated companies in the current year. At MPH, this is reflected in the increase in the value of financial investments. In the first quarter of 2018, the associated company generated preliminary net income (IFRS) of EUR 26.75 million (previous year: EUR -2.39 million). Equity rose to EUR 267.42 million (previous year: EUR 211.56 million). Net asset value (NAV) rose year-on-year from EUR 4.94 to EUR 6.25 per share, well above the current share price.

“Our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG have made a successful start to 2018,” says Patrick Brenske, CEO of MPH. “The healthcare market in Germany has been growing faster than the economy as a whole for years and we are systematically benefiting from this through our investments. With HAEMATO for drugs in the insurance-financed market and with M1 clinics in the private payer market. We are therefore confident that this positive development will continue.”

Due to the sustained positive results of recent years, the Executive Board will propose to the annual general meeting on July 11, 2018 a dividend increase from 12 cents per share to 20 cents per share for the financial year 2017.

The Annual Report 2017 of MPH Health Care AG is available for download at www.mph-ag.de//en/investor-relations

read more

11. May 2018 - Q1 Results 2018

Net asset value rises in Q1/2018 to EUR 6.25 per share and dividend for 2017 to be significantly increased

  • All investments develop positively
  • Dividend increase for 2017 from 12 cents to 20 cents per share

Berlin, May 11, 2018: MPH Health Care AG (ISIN: DE000A0L1H32) will continue to benefit from the successful development of its associated companies in the current year. At MPH, this is reflected in the increase in the value of financial investments. In the first quarter of 2018, the associated company generated preliminary net income (IFRS) of EUR 26.75 million (previous year: EUR -2.39 million). Equity rose to EUR 267.42 million (previous year: EUR 211.56 million). Net asset value (NAV) rose year-on-year from EUR 4.94 to EUR 6.25 per share, well above the current share price.

“Our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG have made a successful start to 2018,” says Patrick Brenske, CEO of MPH. “The healthcare market in Germany has been growing faster than the economy as a whole for years and we are systematically benefiting from this through our investments. With HAEMATO for drugs in the insurance-financed market and with M1 clinics in the private payer market. We are therefore confident that this positive development will continue.”

Due to the sustained positive results of recent years, the Executive Board will propose to the Annual General Meeting on July 11, 2018 a dividend increase from 12 cents per share to 20 cents per share for the financial year 2017.

The Annual Report 2017 of MPH Health Care AG is available for download at www.mph-ag.de/investor-relations

read more

29. March 2018 - Ad hoc – Preliminary IFRS result 2017

Ad hoc of MPH Health Care AG: Preliminary IFRS result 2017

2017: Preliminary IFRS result, net income 31.86 million euros, earnings per share 0.74 euros (previous year: 80.07 million euros, earnings per share 1.87 euros). Equity EUR 240.67 million (previous year: EUR 213.95 million). Net Asset Value per share of EUR 5.62.

MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces its preliminary consolidated IFRS results for the financial year 2017. The preliminary IFRS net income amounted to EUR 31.86 million (EUR 0.74 earnings per share).

HAEMATO AG, which is listed on the Frankfurt Stock Exchange, M1 Kliniken AG and CR Capital Real Estate AG continued to operate successfully in the financial year 2017.

HAEMATO AG was able to increase the consolidated IFRS sales by 5 % to 289.9 million Euro and thereby achieve an EBIT of 9.4 million Euro and a net income of 7.0 million Euro. As in previous years, the dividend paid in June 2017 was 30 cents per share.

M1 Kliniken AG was able to significantly increase its consolidated sales by 31 % to Euro 47.2 million and EBT by 36 % to Euro 7.4 million. In particular, this was due to the opening of six new medical centers in 2017, bringing the total number of M1 centers serving customers nationwide as of December 31, 2017 to 17. The M1 share price rose from EUR 10.80 to EUR 13.18 during the year. The dividend paid in June 2017 was 30 cents per share.

CR Capital Real Estate AG more than doubled its net income to EUR 4.7 million in fiscal year 2017 (previous year: EUR 2.2 million). The consolidated IFRS sales fell to ca. EUR 10.0 million (previous year: EUR 17.5 million). As a result of an ordinary capital reduction pursuant to §§ 222 ff. the stock price of CR Capital Real Estate AG increased from (converted) EUR 19.00 to EUR 20.31 during the year. Due to the extremely positive result, a dividend of EUR 1.00 per share (previous year no dividend) is planned for fiscal 2017.

“We are confident about the further development in 2018. Since 2005, every year the healthcare industry has expanded its gross value added more strongly than the economy as a whole. MPH benefits systematically from this through the growth of HAEMATO AG with drugs in the insurance-financed health care market and M1 Kliniken AG in the private payer market, the so-called second health care market.

“In recent years, a dividend of 12 cents per share has been paid. Based on the positive results of the last three years, we will propose a dividend of 20 cents per share for 2017 to the Annual General Meeting,” says Patrick Brenske, MPH Board Member.

read more

2017

30. October 2017 - Q3 Results 2017

Preliminary IFRS results in the first nine month of 2017

Berlin, 30. October 2017 – MPH Health Care AG: Growth in the third quarter of 2017

  • Value of portfolio holdings increases by 6,68% to EUR 226,67 million
  • Equity ratio increases to 93%
  • Positive development in the healthcare market

In the first nine months of 2017, MPH achieved a preliminary IFRS net income of EUR 11.22 million. Equity increased from EUR 213.95 million in the previous year to EUR 220.03 million.

The share price of MPH rose by 13.2% to EUR 3.43 compared to the third quarter of 2016. The net asset value per share increased to EUR 5.14. The increase in value of MPH’s portfolio holdings resulted in net income for the third quarter of EUR 13.42 million.

MPH’s portfolio companies HAEMATO AG (pharma) and M1 Kliniken AG (clinics) are benefiting from the continued positive development within their growth segments. HAEMATO AG, a specialist in oncology, HIV and other chronic diseases, generates further growth through the high demand for personalized medicine. The market volume is around EUR 10 billion and is growing at an annual rate of 10%.

Kliniken AG benefits from the rapidly growing beauty market. With now more than 50 doctors and 15 locations in Germany, M1 is the leading chain of clinics in major segments of beauty medicine. The growth amounts to approx. 20% -30% p.a.. The company’s aim is to open up further locations also internationally and at the same time to steadily expand the treatment offer in the outpatient area.

The real estate developer CR Capital Real Estate AG increased their sales quota to more than 50% for the first construction phase of the property in Schkeuditz at Leipzig.

read more

31. August 2017 - Interim Report 2017

Interim Report 2017

Berlin, 31 August 2017 – MPH Health Care AG strengthened its activities in the health care market; Net asset value (NAV) per share and share price significantly increased compared to the previous year’s period

• Increase in the net asset value of the share by 35% to EUR 4.83

• Share price rose by 46% to EUR 3.66 (compared to 30 June 2016). Valuation gap partially closed.

This year’s Annual General Meeting decided to rename MPH into “MPH Health Care AG”. This intends to make it even clearer that MPH acts as an investment company aiming at the development of entrepreneurial opportunities in the health care market. As in the previous year a dividend payment of € 0.12 / share was decided.

In the first half of 2017, MPH Health-Care AG successfully continued its growth path. Our company and our holdings were able to record a very gratifying development overall. MPH’s net asset value per share rose by 35% from EUR 3.58 to EUR 4.83 compared to the previous year’s period. At the end of the first half-year of 2017, the share price rose by 45.8% compared to June 30, 2016 (price on June 30, 2016: EUR 2.56 / share). This increase closed some of the remaining valuation gap to about 24%.

The company will provide the interim report for the reporting period from January 1, 2017 to June 30, 2017 as of today.

read more

7. July 2017 - Change in Management Board

First quarter 2017: Preliminary IFRS-Result, period loss – EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

“We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, “said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

read more

28. April 2017 - Q1 Results 2017

First quarter 2017: Preliminary IFRS-Result, period loss – EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

“We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, “said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

read more

17. March 2017 - Preliminary IFRS-Results 2016

2016: Temporary IFRS results, annual net profit of €81.45m, €1.90 profit per share (previous year: €84.10m, €1.96 profit per share). Equity €215.33m (previous year: €139.02m).

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the temporary IFRS group results for fiscal year 2016. In fiscal year 2016, the temporary IFRS annual net profit was €81.45m (€1.90 profit per share).

“HAEMATO AG, M1 Kliniken AG, and CR Capital Real Estate AG holding companies listed in the Frankfurt Stock Exchange operated successfully in 2016.
In fiscal year 2016, HAEMATO achieved an increase in turnover of 20%, an EBIT growth of 63%, and an increase of the annual net profit of 94%.

During the fiscal year, the HAEMATO share price increased from €4.94 to €6.44. As in the previous year, the dividend paid in June 2016 was €0.30 per share.

M1 Kliniken AG expanded its clinic in Berlin to 6 operating theatres and 35 patient beds. After some more openings, 13 M1 centres of competence are now ready to serve our customers throughout Germany. The financial data for 2016 will be published on 31.03.2017.

The M1 share price has almost doubled from €5.34 to €10.55 during the fiscal year. The dividend paid in June 2016 was €0.30 per share.

CR Capital Real Estate AG reported progress in the project developments at the annual general meeting on 18.08.2016. The 2016 financial data will presumably be published in March 2017.

Following last year’s annual net profit of €84.10m, the annual net profit of €81.45m is another record result. This allows us to be confident regarding the further development in 2017. In each year since 2005, the health care industry has expanded its gross value added more strongly than the overall economy. MPH systematically benefits from the growth of HAEMATO AG in the field of pharmaceuticals in the insurance-financed market and through the growth of M1 Kliniken AG in the direct-payer market, the so-called secondary health care market.

The results situation allows us to propose at the annual general meeting a dividend of €0.12 per share, which is the same amount as last year”, note both Patrick Brenske and Dr Christian Pahl, Members of the Board of MPH.

read more

Date of publication

Investor News

Download

2016

29.11.2016

Preliminary IFRS-Results for the first 9 month 2016

30.08.2016

Preliminary IFRS-Results 1st half-year 2016

30.06.2016

Annual General Meeting 2016 30.06.2016

27.05.2016

Preliminary IFRS-Results Q1 2016

27.05.2016

Preliminary IFRS-Results 2015

2015

30.11.2015

Q3 Results 2015

29.05.2015

Q1 Results 2015

31.03.2015

Announcement of the purchase of the majority of the equity of the company CR Capital Real Estate, Berlin

16.03.2015

Preliminary IFRS results 2014

2014

25.11.2014

Q3 Results 2014

03.09.2014

Issuance of new shares, capital increase from company funds, conversion of preference shares into ordinary shares – trading under new WKN and ISIN

29.08.2014

1st half-year 2014

30.05.2014

Q1 Results 2014

14.03.2014

Preliminary IFRS-Results 2013

2013

23.05.2013

Q1 Results 2013

2012

15.11.2012

Q3 Results 2012

10.05.2012

Q1 Results 2012

07.05.2012

MPH AG announces the purchase of roughly 52% of the equity capital of the company WINDSOR AG

16.03.2012

Listing in Entry Standard

08.03.2012

Preliminary results year 2011

2011

15.11.2011

Q3 Results 2011

30.08.2011

Half-year report 2011

04.05.2011

Q1 Results 2011

03.03.2011

Preliminary results for 2010: Increase of 80%

2010

22.02.2010

Provisional figures of 2009

03.05.2010

Numbers 2009

10.05.2010

The figures for the 1st Quarter 2010 confirm a constant growth in Turn-Over and profits for the ongoing financial year

26.07.2010

Yearly Revenue from 2009 (5.079 TEuro) already toped in the first 6 months of 2010 (5.086 Euro).

12.10.2010

Report for third quarter 2010 is available